Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Heidelberg – page 41

737 clinical trials in Heidelberg, Germany across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Heidelberg at a glance
737
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

737 trials in Heidelberg

Open in trial search

Neovascular age-related macular degeneration

Not recruiting

Study on the Effectiveness of OPT-302 and Ranibizumab for Patients with Wet Age-related Macular Degeneration

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:Opthea Limited

Rheumatoid arthritis

Not recruiting

Study on Spironolactone for Treating Active Rheumatoid Arthritis in Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Spironolactone
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Dilated cardiomyopathy

Not recruiting

Study of AB-1002 gene therapy given through coronary arteries in adults with severe (NYHA Class III) heart failure caused by non-ischemic cardiomyopathy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ab-1002
  • Sponsor:Askbio Inc.

Hepato-lenticular degeneration

Not recruiting

Study of Trientine Dihydrochloride (Cufence) to Evaluate Its Effects and Safety in Patients with Wilson's Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Trientine Dihydrochloride
  • Sponsor:Univar Solutions B.V.

Pulmonary hypertension

Not recruiting

Study on Sotatercept for Treating Pulmonary Hypertension in Adults with Heart Failure

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Acceleron Pharma Inc.

Gastric cancer+5

Not recruiting

Study of Nivolumab alone or combined with Ipilimumab for patients with advanced solid tumors (breast, gastric, pancreatic, lung, bladder, or ovarian cancer)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Bristol Myers Squibb International Corporation

Thalassaemia beta

Not recruiting

Long-Term Safety and Efficacy Study of Betibeglogene Autotemcel Gene Therapy for Patients with Transfusion-Dependent Beta-Thalassemia

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Betibeglogene Autotemcel
  • Sponsor:Genetix Biotherapeutics Inc.

Pulmonary arterial hypertension

Not recruiting

Study on Long-Term Safety and Effectiveness of Treprostinil Palmitil for Patients with Pulmonary Arterial Hypertension

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil Palmitil
  • Sponsor:Insmed Inc.

Plasma cell myeloma

Not recruiting

Study on Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed High-Risk Multiple Myeloma Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:University Medical Center Hamburg-Eppendorf

Cardiac amyloidosis

Not recruiting

Study on the Effectiveness and Safety of Eplontersen for Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Eplontersen
  • Sponsor:Ionis Pharmaceuticals Inc.

Non-small cell lung cancer metastatic

Not recruiting

Study on Inupadenant, Carboplatin, and Pemetrexed for Adults with Metastatic Non-Small Cell Lung Cancer After Immunotherapy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Inupadenant Hydrochloride
  • Sponsor:iTeos Belgium

Lung neoplasm malignant

Not recruiting

Study on the Effectiveness of Atezolizumab, Carboplatin, and Nab-Paclitaxel in Patients with Resectable Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Heidelberg

What the registry says about research in the country

01 Cardiovascular Research

Innovative trials focusing on heart failure prevention and treatment of TTR amyloidosis cardiovascular complications. Studies evaluating new therapeutic approaches for pulmonary hypertension.

  • Heart Disease Prevention
  • Cardiovascular Safety Studies
  • Amyloidosis Treatment

Research includes evaluation of novel compounds for heart conditions and preventive therapies.

02 Oncology Studies

Comprehensive research in lung cancer, bladder cancer, and melanoma treatments. Advanced trials for various lymphomas and leukemias using innovative therapeutic approaches.

  • Non-Small Cell Lung Cancer
  • Hematological Malignancies
  • Immunotherapy Combinations

Focus on targeted therapies and immunological approaches in cancer treatment.

03 Transplant Medicine

Groundbreaking research in kidney transplantation with innovative immune system modification approaches. Studies exploring new methods to improve transplant outcomes.

  • Living Donor Procedures
  • Immune System Modulation
  • Post-Transplant Care

Emphasis on developing personalized immunosuppression strategies.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.